Mizuho Securities analyst Eric Criscuolo bumped his price target on Myriad Genetics (NASDAQ: MYGN) to $42.00 (from $38.00) following results but remains on the sidelines with a Neutral rating.

Criscuolo commented, "We are upping our PT to $42 but remain on the sidelines. MYGN reported a decent quarter (top- and bottom-line beat) but conservatively maintained guidance. Our main concern has been reimbursement. We saw positive trends in the hereditary cancer business, but still see some hurdles in Vectra and Prolaris that need to be addressed before we become more constructive. We see the potential of MYGN but remain Neutral until greater certainty emerges/"

For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.

Shares of Myriad Genetics closed at $42.32 yesterday.